ID   VU-SCC-040
AC   CVCL_JL62
SY   VU-SCC-40; 92VU040; 92VU040T
DR   IARC_TP53; 21673
DR   Wikidata; Q54993380
RX   PubMed=8824719;
RX   PubMed=9139877;
RX   PubMed=15735012;
RX   PubMed=23613873;
RX   PubMed=26122845;
RX   PubMed=31541927;
CC   Doubling time: 27 +- 3 hours (PubMed=9139877).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:20250; AJUBA; Simple; p.Ser263fs (c.788_789delCT); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:1509; CASP8; Simple; p.Glu17Lys (c.49G>A); Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:7881; NOTCH1; Simple; p.Asn390Lys (c.1170C>A); Zygosity=Homozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Leu989Val (c.2965C>G); Zygosity=Heterozygous (PubMed=31541927).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15735012; PubMed=23613873).
CC   Omics: Genome sequenced (low read coverage).
DI   NCIt; C4648; Tongue squamous cell carcinoma
DI   ORDO; Orphanet_457252; Squamous cell carcinoma of the oral tongue
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   65Y
CA   Cancer cell line
DT   Created: 15-05-17; Last updated: 19-12-24; Version: 9
//
RX   PubMed=8824719; DOI=10.1002/(SICI)1098-2264(199601)15:1<1::AID-GCC1>3.0.CO;2-8;
RA   Hermsen M.A.J.A., Joenje H., Arwert F., Welters M.J.P., Braakhuis B.J.M.,
RA   Bagnay M., Westerveld A., Slater R.M.;
RT   "Centromeric breakage as a major cause of cytogenetic abnormalities in
RT   oral squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 15:1-9(1996).
//
RX   PubMed=9139877; DOI=10.1002/(SICI)1097-0215(19970502)71:3<410::AID-IJC18>3.0.CO;2-J;
RA   Welters M.J.P., Fichtinger-Schepman A.M.J., Baan R.A., Hermsen M.A.J.A.,
RA   van der Vijgh W.J.F., Cloos J., Braakhuis B.J.M.;
RT   "Relationship between the parameters cellular differentiation,
RT   doubling time and platinum accumulation and cisplatin sensitivity in a
RT   panel of head and neck cancer cell lines.";
RL   Int. J. Cancer 71:410-415(1997).
//
RX   PubMed=15735012; DOI=10.1158/0008-5472.CAN-04-3665;
RA   van Zeeburg H.J.T., Snijders P.J.F., Pals G., Hermsen M.A.J.A.,
RA   Rooimans M.A., Bagby G., Soulier J., Gluckman E., Wennerberg J.,
RA   Leemans C.R., Joenje H., Brakenhoff R.H.;
RT   "Generation and molecular characterization of head and neck squamous
RT   cell lines of Fanconi anemia patients.";
RL   Cancer Res. 65:1271-1276(2005).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004; PMCID=PMC7372097;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//